SKINBIO THERAP LS-01
Research SKINBIO THERAP LS-01 (5KW) on Bullrun: market cap EUR 23.84M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker5KW
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 23.84M
- Financial periodFY2025
- RevenueGBP 4.64M
- Revenue growth283.7%
- Net income-GBP 696.25K
- Free cash flow-GBP 1.39M
- Gross margin61.6%
Valuation Snapshot
latest market cap is EUR 23.84M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 4.64M | -GBP 696.25K | -GBP 1.39M | 61.6% | 0 | GBP 4.78M | GBP 993.47K | GBP 9.42M |
| FY2024 | GBP 1.21M | -GBP 2.88M | -GBP 2.92M | 56.5% | -0.02 | GBP 800.90K | GBP 818.74K | GBP 2.97M |
| FY2023 | GBP 132.06K | -GBP 2.84M | -GBP 2.81M | 64.5% | -0.02 | GBP 1.31M | GBP 100.65K | GBP 1.99M |
| FY2022 | GBP 74.76K | -GBP 2.79M | -GBP 2.77M | 60.6% | -0.02 | GBP 1.80M | GBP 127.86K | GBP 2.48M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 23.84M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About SKINBIO THERAP LS-01
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SKINBIO THERAP LS-01's market cap?
SKINBIO THERAP LS-01's market capitalization is EUR 23.84M.
What does SKINBIO THERAP LS-01 do?
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development.